Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Apr
21
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Elisrasib Demonstrates High DCR in KRAS G12C NSCLC
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo